06 May 2013
B P Collins supports RWS in its acquisition of PharmaQuest for £2.3 Million
At the end of April 2013, the B P Collins corporate and commercial team acted for RWS Holdings plc, in the acquisition of the entire issued share capital of PharmaQuest Limited for a cash consolidation of £2,300,000.
As Europe's leading provider of intellectual property support services and commercial translations, RWS acquired PharmaQuest which specialises in high quality translations and linguistic validation of patient reported outcome measures resulting from clinical trials.
Andrew Brode Executive chairman at RWS stated that “[RWS] is pleased to have acquired PharamQuest, whose progress we have monitored for several years. It is an attractive business with excellent margins and group growth prospects in a rapidly expanding, specialist sector. It will immediately enhance RWS group earnings and further strengthen our position as a leading provider of commercial and medical translations.”
”We look forward to growing PharmaQuest, with the benefit of the group's infrastructure and marketing resources, and to broadening our market share in the medical pharmaceutical industries.”
Our corporate and commercial partner David Smellie, who managed the legal requirements of the deal commented; ''We are delighted to have been asked to assist Chalfont St Peter based RWS in this acquisition and aid their continual growth, both by way of acquisition and organically. This is the second acquisition on which we have assisted and it has been a pleasure working with them to complete this acquisition.
David Smellie, partner